Tirzepatide

Mechanism

Tirzepatide is a dual agonist at both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — a single molecule engineered to activate two incretin pathways simultaneously. The GLP-1 component delivers the same appetite suppression and gastric motility effects as semaglutide. The GIP component adds a second metabolic route: GIP receptors on adipocytes are recruited directly, improving insulin sensitivity and fatty acid metabolism in a pathway that is independent of and complementary to GLP-1 signaling.

In SURMOUNT-1 clinical trial data, tirzepatide at 15 mg produced 20–22% mean body weight loss — substantially more than semaglutide's 15% ceiling. The mechanistic argument for the difference is that the GIP axis contributes both additional metabolic efficiency and, in some analyses, better lean-mass preservation relative to the degree of deficit induced. The appetite suppression is at least as powerful as semaglutide, and the additional GIP component appears to do genuine metabolic work beyond just eating less.

Like semaglutide, the weight loss mechanism is primarily sustained caloric deficit. Tirzepatide doesn't directly burn fat — it makes it dramatically easier to eat less, while the GIP axis improves what your body does with the deficit.

Typical protocol

• Starter: 2.5 mg SC weekly × 4 weeks → 5 mg × 4 weeks → 7.5 mg × 4 weeks → 10 mg × 4 weeks → 12.5 mg × 4 weeks → 15 mg maintenance. Advance only when the current dose is tolerated and progress has stalled.
• Advanced: Many users find their effective ceiling below 15 mg. If losing at 10 mg with acceptable tolerance, stay there. Escalate only when weight loss has genuinely plateaued for 4+ weeks at a given dose.
• Cycle length: Continuous for the weight-loss phase. Taper before stopping — the rebound from abrupt cessation after extended use is real.
• Reconstitution: 5 mg vial + 2 mL BAC water → 2.5 mg/mL. On a U-100 insulin syringe: 10 IU = 0.1 mL = 250 mcg (0.25 mg). For the 2.5 mg starting dose: 100 IU = 1.0 mL. Store reconstituted vials at 4°C; use within 28 days. Same day each week, abdomen or thigh rotating sites.

Who it's for

Fat loss goal, particularly users who have not responded adequately to semaglutide, have higher baseline insulin resistance, or carry more significant metabolic dysfunction. The dual-pathway mechanism also makes it the better choice for users who have plateaued on a GLP-1-only approach. Higher baseline body fat and metabolic syndrome phenotype tend to respond better to tirzepatide than to semaglutide. Lean bodybuilders should not run either — this is a tool for meaningful weight loss, not a final-polish cut.

Stacks well with

• aod 9604 5mg — complementary mechanisms; AOD-9604 drives direct lipolysis at adipocyte beta-3 receptors while tirzepatide manages the deficit through dual incretin signaling. Stacking makes sense later in a cut when GLP-1/GIP-driven progress slows.

Do NOT combine with semaglutide 5mg — dual GLP-1 coverage amplifies GI side effects with no additive fat-loss benefit.

Watch-outs

• GI profile (nausea, constipation, delayed gastric emptying) is similar to semaglutide and often reported as milder at equivalent weight-loss doses. Still titrate slowly — impatience on the ramp costs weeks of nausea.
• Same lean-mass vulnerability as semaglutide. High protein intake and resistance training are required, not optional, for preserving muscle during rapid weight loss at these doses.
• Do not run on someone already underweight or with a history of disordered eating. The appetite suppression is aggressive enough to push compromised eating patterns into dangerous territory.
• At 15 mg the GI side effects become more pronounced for some users. Staying at a lower effective dose is a valid strategy if outcomes are adequate.